Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialResearch in context

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialResearch in context

Summary: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralising IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further incre...

Full description

Bibliographic Details
Main Authors: María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela-Silva, Waldemar Baldoquín-Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mujica Romero, Oscar Samón-Tabio, Pablo Velazco-Villares, Juan Pablo Bacallao-Castillo, Ernesto Licea-Martín, Misladys Rodríguez-Ortega, Nuris Herrera-Marrero, Esperanza Caballero-González, Liudmila Egües-Torres, Reinaldo Duartes-González, Serguey García-Blanco, Suzette Pérez-Cabrera, Santos Huete-Ferreira, Kirenia Idalmis-Cisnero, Omayda Fonte-Galindo, Dania Meliá-Pérez, Ivonne Rojas-Remedios, Delaram Doroud, Mohammad Mehdi Gouya, Alireza Biglari, Sonsire Fernández-Castillo, Yanet Climent-Ruiz, Yury Valdes-Balbín, Dagmar García-Rivera, Patrick Van der Stuyft, Vicente Verez-Bencomo
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:The Lancet Regional Health. Americas
Subjects:
Conjugate-vaccine
SARS-COV-2
COVID-19 vaccine
Heterologous scheme
RBD-subunit vaccine
Vaccine efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2667193X2200240X

Similar Items

Similar Items